Physician profile
David W Baker
NPI 1942596481
$10,479.06
in general payments reported to CMS, 2019-2025
54 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $1,156 · 2021: $1,707 · 2022: $1,566 · 2023: $1,822 · 2024: $1,456 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,756 · Education: $51.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,755.94 |
| Education | $51.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.77 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,182.69 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $742.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $630.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $567.37 | 2019-2023 | |
| Amgen INC. | $552.68 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.00 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $394.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $356.49 | 2019-2024 | Eliquis, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $315.00 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $286.75 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.20 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $270.26 | 2019-2020 | |
| Pfizer INC. | $205.98 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $194.22 | 2021-2024 | Linzess |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.